Metagenomic sequencing
Empowering clinical decision-making, improving patient outcomes
When traditional, first-line testing approaches, including culture and antigen staining, and other advanced testing methods, such as a multiplex polymerase chain reaction (PCR) panel, fail to yield a diagnosis for systemic or deep-seated infections, metagenomic sequencing can provide accurate answers to guide care.
Our full menu of metagenomic sequencing assays includes cerebrospinal fluid (CSF) testing from Mayo Clinic Laboratories as well as plasma and bronchoalveolar lavage fluid (BALF) testing, offered in collaboration with Karius. Backed by data and centered around patient need, these tests can accurately identify the causative agent and support clinical decision-making. Test results empower clinicians to select targeted therapies for their patients, which reduces the need for invasive procedures and improves patient outcomes.
1,000+
1,000+ pathogens detected through plasma metagenomic sequencing
500+
500+ pathogens detected through BALF metagenomic sequencing
1,000+
1,000+ pathogens detected through CSF metagenomic sequencing
Test menu
Bronchoalveolar lavage fluid testing
The Karius Focus™ test metagenomic sequencing assay detects and classifies more than 500 pathogens, including bacteria, fungi, parasites, and DNA viruses, using just 1 mL of bronchoalveolar fluid (BALF).
Cerebrospinal fluid testing
Mayo Clinic Laboratories’ shotgun metagenomic sequencing assay detects and identifies more than 1,000 types of bacteria, DNA and RNA viruses, fungi, and parasites by holistically sequencing all the DNA and RNA present in cerebrospinal fluid.
Plasma testing
The Karius Spectrum Test® next-generation sequencing assay detects microbial cell-free DNA from more than 1,000 pathogens, including bacteria, fungi, DNA viruses, and parasites using a single blood draw.